Renal cell carcinoma (RCC) is one of the most lethal urologic malignancies. Its incidence continues to rise worldwide with a rate of 2% per year. Approximately, one-third of the RCC patients are diagnosed at advanced stages due to the asymptomatic nature of its early stages. This represents a great hurdle, since RCC is largely chemoresistant/radioresistant, and targeted therapy of mRCC still has limited efficacy. The 5-year survival rate of metastatic RCC (mRCC) is only around 10%. Adoptive cell transfer (ACT), a particular form of cell-based anticancer immunotherapy, is a promising approach in the treatment of mRCC. The vaccination principle, however, faces unique challenges that preclude the efficacy of ACT. In this article, we review the main challenges of ACT in the treatment of mRCC and describe multiple methods that can be used to overcome these challenges. In this respect, the ultimate purpose of this review is to provide a descriptive tool by which to improve the development of novel protocols for ACT of mRCC.

Institute of Immunology 2nd Faculty of Medicine and Motol University Hospital Charles University 5 Uvalu 84 150 06 Prague Czech Republic

Zobrazit více v PubMed

Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016;9:45–52. PubMed PMC

Shea MW. A proposal for a targeted screening program for renal cancer. Front Oncol. 2013;3:207. doi: 10.3389/fonc.2013.00207. PubMed DOI PMC

Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528. doi: 10.7573/dic.212528. PubMed DOI PMC

Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adoptive cell therapy: past, present and future. Immunotherapy. 2017;9(2):183–196. doi: 10.2217/imt-2016-0112. PubMed DOI

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi: 10.1126/science.aaa4967. PubMed DOI PMC

Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control. 2013;20(4):289–297. doi: 10.1177/107327481302000406. PubMed DOI PMC

Tang X, Liu T, Zang X, Liu H, Wang D, Chen H, et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS ONE. 2013;8(5):e62847. doi: 10.1371/journal.pone.0062847. PubMed DOI PMC

Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60. doi: 10.1016/j.immuni.2013.07.002. PubMed DOI PMC

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646–2655. doi: 10.1158/1078-0432.CCR-10-0041. PubMed DOI

Bellone M, Calcinotto A, Corti A. Won’t you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology. 2012;1(6):986–988. doi: 10.4161/onci.20213. PubMed DOI PMC

Torcellan T, Stolp J, Chtanova T. In vivo imaging sheds light on immune cell migration and function in cancer. Front Immunol. 2017;8:309. doi: 10.3389/fimmu.2017.00309. PubMed DOI PMC

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122(3):899–910. doi: 10.1172/JCI45817. PubMed DOI PMC

Bougherara H, Mansuet-Lupo A, Alifano M, Ngo C, Damotte D, Le Frere-Belda MA, et al. Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. Front Immunol. 2015;6:500. doi: 10.3389/fimmu.2015.00500. PubMed DOI PMC

Idorn M, Thor Straten P. Chemokine receptors and exercise to tackle the inadequacy of T cell homing to the tumor site. Cells. 2018 doi: 10.3390/cells7080108. PubMed DOI PMC

Nayar S, Dasgupta P, Galustian C. Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies—a review. Oncoimmunology. 2015;4(4):e1002720. doi: 10.1080/2162402X.2014.1002720. PubMed DOI PMC

Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011;71(17):5601–5605. doi: 10.1158/0008-5472.CAN-11-1316. PubMed DOI

Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14(5):468–474. doi: 10.1007/s11912-012-0257-5. PubMed DOI PMC

Giraldo NA, Becht E, Pages F, Skliris G, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, Lupo A, Alifano M, Damotte D, Cazes A, Triebel F, Freeman GJ, Dieu-Nosjean MC, Oudard S, Fridman WH, Sautes-Fridman C. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031–3040. doi: 10.1158/1078-0432.CCR-14-2926. PubMed DOI

Geissler K, Fornara P, Lautenschlager C, Holzhausen HJ, Seliger B, Riemann D. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology. 2015;4(1):e985082. doi: 10.4161/2162402X.2014.985082. PubMed DOI PMC

Strizova Z, Taborska P, Stakheev D, Partlova S, Havlova K, Vesely S, Bartunkova J, Smrz D. NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. Urol Oncol. 2019;37(7):503–509. doi: 10.1016/j.urolonc.2019.03.014. PubMed DOI

Crossey F, Marx S, Holters S, Schmitt K, Bohle RM, Schmidt T, et al. Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure. Urol Oncol. 2018;36(9):402e1–402e10. doi: 10.1016/j.urolonc.2018.06.002. PubMed DOI

Mayor P, Starbuck K, Zsiros E. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol. 2018;150(2):361–369. doi: 10.1016/j.ygyno.2018.05.024. PubMed DOI PMC

Voigt H, Kleeberg UR. Malignes melanom. Berlin: Springer; 1986. p. 185.

Cox TR, Erler JT. Fibrosis and cancer: Partners in crime or opposing forces? Trends Cancer. 2016;2(6):279–282. doi: 10.1016/j.trecan.2016.05.004. PubMed DOI

Joung JW, Oh HK, Lee SJ, Kim YA, Jung HJ. Significance of intratumoral fibrosis in clear cell renal cell carcinoma. J Pathol Transl Med. 2018;52(5):323–330. doi: 10.4132/jptm.2018.07.21. PubMed DOI PMC

Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171–6180. doi: 10.1158/0008-5472.CAN-10-0153. PubMed DOI PMC

Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev. 2012;32(5):1078–1091. doi: 10.1002/med.20238. PubMed DOI

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018;19(6):799–811. doi: 10.1016/S1470-2045(18)30193-1. PubMed DOI

Zhang E, Xu H. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol. 2017;10(1):1. doi: 10.1186/s13045-016-0379-6. PubMed DOI PMC

Muller WA. Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol. 2011;6:323–344. doi: 10.1146/annurev-pathol-011110-130224. PubMed DOI PMC

Berman ME, Xie Y, Muller WA. Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. J Immunol. 1996;156(4):1515–1524. PubMed

Dasgupta B, Dufour E, Mamdouh Z, Muller WA. A novel and critical role for tyrosine 663 in platelet endothelial cell adhesion molecule-1 trafficking and transendothelial migration. J Immunol. 2009;182(8):5041–5051. doi: 10.4049/jimmunol.0803192. PubMed DOI PMC

Andersen R, Westergaard MCW, Kjeldsen JW, Muller A, Pedersen NW, Hadrup SR, et al. T-cell responses in the microenvironment of primary renal cell carcinoma-implications for adoptive cell therapy. Cancer Immunol Res. 2018;6(2):222–235. doi: 10.1158/2326-6066.CIR-17-0467. PubMed DOI

Tian JQ, Wang ZP, Rodriguez R, Fu JS, Lu JZ, Ma BL. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Urology. 2006;67(5):1093–1098. doi: 10.1016/j.urology.2005.11.030. PubMed DOI

de Bruyn M, Wei Y, Wiersma VR, Samplonius DF, Klip HG, van der Zee AG, Yang B, Helfrich W, Bremer E. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells. Clin Cancer Res. 2011;17(17):5626–5637. doi: 10.1158/1078-0432.CCR-11-0303. PubMed DOI

Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Moller P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut. 2005;54(5):661–665. doi: 10.1136/gut.2004.052696. PubMed DOI PMC

Cacan E. Enhancing sensitivity of chemoresistant ovarian cancer cells to TRAIL and FAS mediated apoptosis by radiation. Turk Hij Den Biyol Derg. 2017;74(3):185–192. doi: 10.5505/TurkHijyen.2017.12499. DOI

de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016;23(5):733–747. doi: 10.1038/cdd.2015.174. PubMed DOI PMC

Hinrichs C, Borman Z, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern S, Logun C, et al. Adoptively transferred effector cells derived from naïve rather than central memory CD8 T cells mediate superior antitumor immunity. PNAS. 2009;106:17469–17474. doi: 10.1073/pnas.0907448106. PubMed DOI PMC

Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245–1256. doi: 10.1016/j.bbmt.2010.03.014. PubMed DOI PMC

Poschke I, Lovgren T, Adamson L, Nystrom M, Andersson E, Hansson J, et al. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother. 2014;63(10):1061–1071. doi: 10.1007/s00262-014-1575-2. PubMed DOI PMC

Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4*CD25* regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169–1177. doi: 10.1200/JCO.2005.03.6830. PubMed DOI

Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13:2075–2081. doi: 10.1158/1078-0432.CCR-06-2139. PubMed DOI

Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674–6682. doi: 10.1158/1078-0432.CCR-07-5212. PubMed DOI

Nagaraj S, Youn JI, Weber H, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010;16(6):1812–1823. doi: 10.1158/1078-0432.CCR-09-3272. PubMed DOI PMC

Nicholson IC, Mavrangelos C, Bird DR, et al. PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20. Cell Immunol. 2012;275(1–2):12–18. doi: 10.1016/j.cellimm.2012.04.002. PubMed DOI

Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 2006;55(1):96–103. doi: 10.1007/s00262-005-0706-1. PubMed DOI PMC

Elevated PD-L1 and PECAM-1 as Diagnostic Biomarkers of Acute Rejection in Lung Transplantation

Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy

The Role of miR-155 in Antitumor Immunity

Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?